Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GTBP NASDAQ:INAB NASDAQ:JBIO NASDAQ:SCNI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGTBPGT Biopharma$1.81-2.7%$2.62$1.72▼$4.10$6.09M1.33105,373 shs38,748 shsINABIN8bio$2.11-0.9%$2.64$2.05▼$25.48$6.45MN/A140,564 shs125,511 shsJBIOJade Biosciences$6.89-4.2%$0.00$6.57▼$105.00$6.04M1.06159,336 shs143,073 shsSCNIScinai Immunotherapeutics$1.47+0.7%$2.31$1.40▼$6.18$1.46M1.862.99 million shs197,300 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGTBPGT Biopharma-2.69%-12.14%-41.61%-22.32%-30.65%INABIN8bio-0.94%-13.52%-2.31%-58.51%-91.63%JBIOJade Biosciences-4.17%-16.79%-36.20%+688,999,900.00%+688,999,900.00%SCNIScinai Immunotherapeutics+0.68%-28.64%-35.24%-47.24%-68.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGTBPGT Biopharma2.0079 of 5 stars3.84.00.00.00.00.00.6INABIN8bio3.2394 of 5 stars3.55.00.00.00.62.51.3JBIOJade Biosciences1.829 of 5 stars3.50.00.00.00.91.70.6SCNIScinai Immunotherapeutics1.2151 of 5 stars0.05.00.00.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGTBPGT Biopharma 3.50Strong Buy$11.00507.73% UpsideINABIN8bio 3.00Buy$180.008,430.81% UpsideJBIOJade Biosciences 3.00Buy$15.00117.71% UpsideSCNIScinai Immunotherapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SCNI, GTBP, INAB, and JBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.006/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/AINABIN8bioN/AN/AN/AN/A$6.00 per shareN/AJBIOJade BiosciencesN/AN/AN/AN/A$92.88 per shareN/ASCNIScinai Immunotherapeutics$660K2.23N/AN/A$5.10 per share0.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGTBPGT Biopharma-$13.16M-$5.69N/AN/AN/AN/A-1,033.08%-223.20%8/13/2025 (Estimated)INABIN8bio-$30.44M-$13.57N/AN/AN/AN/A-218.85%-139.59%8/14/2025 (Estimated)JBIOJade Biosciences-$69.63M-$59.65N/A∞N/AN/A-60.01%-54.32%N/ASCNIScinai Immunotherapeutics$4.80M-$9.57N/A∞N/AN/AN/A-40.60%8/21/2025 (Estimated)Latest SCNI, GTBP, INAB, and JBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025INABIN8bio-$1.50N/AN/AN/AN/AN/A8/13/2025Q2 2025GTBPGT Biopharma-$0.68N/AN/AN/AN/AN/A5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/A5/8/2025Q1 2025INABIN8bio-$1.80-$2.10-$0.30-$0.07N/AN/A5/7/2025Q4 2024SCNIScinai ImmunotherapeuticsN/A-$10.40N/A-$10.40N/A$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGTBPGT BiopharmaN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ASCNIScinai ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGTBPGT BiopharmaN/A0.730.73INABIN8bio0.014.304.30JBIOJade BiosciencesN/A32.0132.01SCNIScinai Immunotherapeutics0.061.321.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGTBPGT Biopharma8.15%INABIN8bio92.05%JBIOJade BiosciencesN/ASCNIScinai Immunotherapeutics58.41%Insider OwnershipCompanyInsider OwnershipGTBPGT Biopharma3.40%INABIN8bio15.50%JBIOJade Biosciences24.90%SCNIScinai Immunotherapeutics60.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGTBPGT Biopharma83.27 million3.16 millionNo DataINABIN8bio203.03 million2.56 millionNot OptionableJBIOJade Biosciences20841,000632,000N/ASCNIScinai Immunotherapeutics201.00 million391,000Not OptionableSCNI, GTBP, INAB, and JBIO HeadlinesRecent News About These CompaniesScinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TENJuly 29, 2025 | prnewswire.comScinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025June 12, 2025 | prnewswire.comScinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.June 5, 2025 | prnewswire.comScinai Immunotherapeutics Reports Strong CDMO GrowthJune 2, 2025 | tipranks.comScinai Immunotherapeutics Ltd.: Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash BurnMay 30, 2025 | finanznachrichten.deScinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash BurnMay 30, 2025 | prnewswire.comScinai Announces Annual Financial Results for 2024May 7, 2025 | prnewswire.comScinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin DiseasesMay 1, 2025 | prnewswire.comScinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological ConditionsMarch 27, 2025 | prnewswire.comScinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025March 17, 2025 | prnewswire.comSCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENTMarch 5, 2025 | prnewswire.comScinai Immunotherapeutics Ltd. (SCNI)January 28, 2025 | ca.finance.yahoo.comScinai Immunotherapeutics (NASDAQ: SCNI) to Engage Investors at January ConferencesJanuary 7, 2025 | theglobeandmail.comScinai to Connect with Investors and Pharma Leaders at Upcoming Key US ConferencesJanuary 6, 2025 | prnewswire.comScinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.December 16, 2024 | prnewswire.comProf. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory BoardDecember 5, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory BoardDecember 3, 2024 | theglobeandmail.comThere Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of ProfitabilityNovember 29, 2024 | uk.finance.yahoo.comDr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory BoardNovember 27, 2024 | prnewswire.comScinai Immunotherapeutics Reports Financial Turnaround and GrowthNovember 26, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat?By Jeffrey Neal Johnson | July 24, 2025View Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat?SCNI, GTBP, INAB, and JBIO Company DescriptionsGT Biopharma NASDAQ:GTBP$1.81 -0.05 (-2.69%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.86 +0.05 (+2.76%) As of 08/1/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.IN8bio NASDAQ:INAB$2.11 -0.02 (-0.94%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.14 +0.03 (+1.37%) As of 08/1/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Jade Biosciences NASDAQ:JBIO$6.89 -0.30 (-4.17%) As of 08/1/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Scinai Immunotherapeutics NASDAQ:SCNI$1.47 +0.01 (+0.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.42 -0.05 (-3.40%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
